1-20 of 15,890 results for subject:Cancer
Librarians' tools
- Search time
- 0.539 seconds
- Solr query time
- 0.025 seconds
- Search query
- subject:Cancer
- We searched for
- subject_t:Cancer OR subject_t:Oncology OR subject_t:Sarcoma OR subject_ses:8937
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential impact of a diagnosis of cancer during (a) pregnancy and (b) maternity leave on a mother's physical health, mental wellbeing and access to treatment.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential impact of a diagnosis of cancer during (a) pregnancy and (b) maternity leave on a mother's physical health, mental wellbeing and access to treatment.
The Government recognises that a cancer diagnosis during pregnancy or maternity leave can have a significant impact on women and their families.
The National Cancer Plan sets out how we will provide support to people with cancer before, during, and after their treatment, including for pregnant or postnatal women. Everyone should get a personalised needs assessment and personal cancer plan that takes into account their wider psychological and social needs, including the impact of pregnancy where relevant.
Health professionals should provide integrated care for pregnant women facing serious physical illnesses and mental health challenges. Significant progress has been made across England in recent years to transform and increase access to specialist perinatal mental health services.
To ask the Secretary of State for Health and Social Care, whether the review of orphan medicines regulation required by the Rare Cancers Act 2026 will consider the full pathway from regulatory authorisation to NHS patient access, including evidence generation, health technology assessment and uptake of treatments for rare cancers.
To ask the Secretary of State for Health and Social Care, whether the review of orphan medicines regulation required by the Rare Cancers Act 2026 will consider the full pathway from regulatory authorisation to NHS patient access, including evidence generation, health technology assessment and uptake of treatments for rare cancers.
The review required by the Rare Cancers Act 2026 will focus on the regulatory framework for orphan medicines used in the diagnosis, prevention and treatment of rare cancers. It will consider international regulatory approaches and assess whether the United Kingdom's regulatory framework is effective in encouraging research and development of treatments for rare cancers. We will set out further details in the usual way in due course.
To ask the Secretary of State for Health and Social Care, with reference to Action 25 of the National Cancer Plan, which NHS trusts have been identified as requiring additional oncology training places; and what proportion of those areas are in rural versus non-rural communities.
To ask the Secretary of State for Health and Social Care, with reference to Action 25 of the National Cancer Plan, which NHS trusts have been identified as requiring additional oncology training places; and what proportion of those areas are in rural versus non-rural communities.
Reducing inequalities in cancer care is a priority for this Government. As part of the National Cancer Plan for England, the Government committed to creating additional training places for cancer consultants in areas with the greatest workforce need, including rural and coastal communities. NHS England is currently working through implementation arrangements.
Work is progressing on the expansion of 4,500 resident doctor posts, and is currently for the initial 1,000, although it is not intended specifically to address Action 25 set out in the National Cancer Plan. NHS England uses an allocations methodology that recommends the establishment of additional posts in geographies that are relatively under-resourced. As rural geographies tend to have fewer postgraduate medical training posts per need-adjusted population than urban ones, such geographies would be prioritised for expansion when we increased numbers of training opportunities.
NHS England is currently working with regional colleagues, Postgraduate Medical and Dental Education and trusts to identify additional resident doctor posts. NHS England cannot yet confirm how many of these additional posts will be in clinical oncology or medical oncology, as trusts have yet to send a complete list of expressions of interest in each training programme. Following receipt of the expressions of interest supporting the initial 1,000 posts, we will be able to assess that expansion and provide additional advice for the expansion of the remaining 3,500 posts which will follow in 2028 and 2029.
To ask His Majesty's Government whether the forthcoming Cancer Manuals will address inequalities in care for patients with low-grade glioma.
To ask His Majesty's Government whether the forthcoming Cancer Manuals will address inequalities in care for patients with low-grade glioma.
The Department and NHS England are reviewing the process for developing cancer manuals, including the criteria to use in relation to rare tumour types where survival improvements have been the slowest, as well as accountability mechanisms and consultation processes. We will provide further updates in the usual way in due course.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the risks to patients arising from the promotion and sale online of ivermectin and other unlicensed or unproven products as treatments for cancer; and what steps the Medicines and Healthcare products Regulatory Agency...
To ask the Secretary of State for Health and Social Care, what assessment she has made of the risks to patients arising from the promotion and sale online of ivermectin and other unlicensed or unproven products as treatments for cancer; and what steps the Medicines and Healthcare products Regulatory Agency...
The Medicines and Healthcare products Regulatory Agency (MHRA) recognises the risks associated with the promotion and sale of ivermectin and other unauthorised or unproven products as treatments for cancer. Ivermectin is not authorised in the United Kingdom for the treatment or prevention of cancer, and claims that it can treat, prevent or cure cancer may mislead patients and risk them delaying or foregoing proven medical treatment.
The MHRA takes robust enforcement action against the illegal promotion, advertising and supply of unauthorised medicines, including online. Through its Criminal Enforcement Unit, the MHRA investigates suspected breaches of the Human Medicines Regulations 2012, and has the power to seize illicit medicines and, where appropriate, pursue prosecution.
To ask the Secretary of State for Health and Social Care, what recent steps her Department has taken to increase funding for cancer research.
To ask the Secretary of State for Health and Social Care, what recent steps her Department has taken to increase funding for cancer research.
I refer the Hon Member to the National Cancer Plan for England, published in February, which sets out the steps we are taking in a range of areas to improve cancer diagnosis, treatment, and outcomes, including for research and clinical trials. The National Cancer Plan for England is available at the following link:
I also refer the Hon Member to the answer provided on 24 February 2026 to the Hon Member for Sheffield South East to Question 113042.
To ask the Secretary of State for Health and Social Care, what recent discussions her Department has had with (a) patients and (b) medical professionals on increasing (i) investment and (ii) clinical trials into cancer treatments.
To ask the Secretary of State for Health and Social Care, what recent discussions her Department has had with (a) patients and (b) medical professionals on increasing (i) investment and (ii) clinical trials into cancer treatments.
I refer the Hon Member to the National Cancer Plan for England, published in February, which sets out the steps we are taking in a range of areas to improve cancer diagnosis, treatment, and outcomes, including for research and clinical trials. The National Cancer Plan for England is available at the following link:
I also refer the Hon Member to the answer provided on 24 February 2026 to the Hon Member for Sheffield South East to Question 113042.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to prioritise access to special treatment for patients with rare cancers such as lymphoma and expand access to specialist expertise.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to prioritise access to special treatment for patients with rare cancers such as lymphoma and expand access to specialist expertise.
I refer the Hon Member to the answer provided on 17 July 2026 in response to Question 18279.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of integrating evidence-based nutritional, physical activity and lifestyle interventions more routinely alongside medical treatment for cancer patients.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of integrating evidence-based nutritional, physical activity and lifestyle interventions more routinely alongside medical treatment for cancer patients.
I refer the Hon Member to the Department’s strategy on Living with and Beyond Cancer in Chapter 4 of the National Cancer Plan available at the link below, which examines these and other issues in detail:
To ask the Secretary of State for Health and Social Care, if she has made an assessment of the potential (a) financial and (b) other challenges faced by cancer patients in accessing appropriate evidence-based nutritional, lifestyle and wellbeing support alongside their treatment.
To ask the Secretary of State for Health and Social Care, if she has made an assessment of the potential (a) financial and (b) other challenges faced by cancer patients in accessing appropriate evidence-based nutritional, lifestyle and wellbeing support alongside their treatment.
I refer the Hon Member to the Department’s strategy on Living with and Beyond Cancer in Chapter 4 of the National Cancer Plan available at the link below, which examines these and other issues in detail:
To ask the Secretary of State for Health and Social Care, whether guidance is available to NHS cancer services on providing patients with evidence-based information on nutrition, physical activity and lifestyle alongside conventional cancer treatment.
To ask the Secretary of State for Health and Social Care, whether guidance is available to NHS cancer services on providing patients with evidence-based information on nutrition, physical activity and lifestyle alongside conventional cancer treatment.
I refer the Hon Member to the Department’s strategy on Living with and Beyond Cancer in Chapter 4 of the National Cancer Plan available at the link below, which examines these and other issues in detail:
To ask His Majesty's Government whether NHS England plans to publish the evidence base underpinning the decision to revise the CAR-T tariff; and what assessment they have made of the potential impact of the revised tariff on patients' access to treatment.
To ask His Majesty's Government whether NHS England plans to publish the evidence base underpinning the decision to revise the CAR-T tariff; and what assessment they have made of the potential impact of the revised tariff on patients' access to treatment.
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to support Enhertu being made available in England.
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to support Enhertu being made available in England.
I refer the Hon. Members to the answer provided on 17 July to Question 17825.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve (a) mental and (b) emotional support for children whose parents have been diagnosed with cancer.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve (a) mental and (b) emotional support for children whose parents have been diagnosed with cancer.
To ask His Majesty's Government what assessment they have made of the extent to which genomic and biomarker testing is routinely embedded at the point of cancer diagnosis across NHS England.
To ask His Majesty's Government what assessment they have made of the extent to which genomic and biomarker testing is routinely embedded at the point of cancer diagnosis across NHS England.
Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service (NHS GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory, which includes tests for over 200 cancer clinical indications.
From April 2026 NHS England has been embedding a new operating model for delivery of the NHS GMS through seven NHS GMS Lead Providers. Each NHS GMS will deliver a cancer genomics clinical function to bring together multi-profession leadership to embed and drive improvements in end to end cancer genomics pathways and deliver genomic testing in clinically relevant turnaround times. The programme also includes expanding the number of cellular pathology genomic centres to streamline the cancer diagnostic sample pathway and support timely return of genomic test results to inform clinical management and enable cancer patients to access innovative therapies.
In addition, the National Cancer Plan identified diagnostic technologies as a strategic research priority for improving survival rates for those living with or treated for cancer. The Office for Life Sciences has funded a primary care intervention study via the National Institute for Health and Care Research Health Technology Assessment Programme to assess the clinical and cost effectiveness of the use of multi-cancer detection tests in primary care to support future commissioning of diagnostic biomarkers in diagnostic pathways.
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to reduce the time taken to open cancer clinical trials in the NHS, and what assessment they have made of the potential impact of delays in opening cancer clinical trials for new treatments.
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to reduce the time taken to open cancer clinical trials in the NHS, and what assessment they have made of the potential impact of delays in opening cancer clinical trials for new treatments.
As set out in the Life Sciences Sector Plan and reinforced in the 10-Year Health Plan for England, the Department is committed to cutting the current time it takes to get a clinical trial set up, to under 150 days. I refer the Hon Member to the report, including actions and progress so far against the 150-day target, published by the Government on 9 July 2026, which is available at the following link:
https://www.gov.uk/government/publications/life-sciences-sector-plan-one-year-on
The National Cancer Plan, available at the link below, outlines actions to increase the speed, scale, and reliability of cancer clinical trials in detail:
https://www.gov.uk/government/publications/national-cancer-plan-for-england
The 10-Year Health Plan for England, available at the link below, commits to embedding research as a core component of care:
https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future
An update on the forthcoming 10 Year Workforce Plan will be available in due course.
In July 2026, the Department, through the National Institute for Health and Care Research (NIHR), published the Research Workforce Update for England which aims to ensure that research opportunities and careers are accessible to a broader range of professions and communities, helping to develop a sustainable and inclusive research workforce across all health and social care settings and geographies for the future. The Research Workforce Update for England is available at the following link:
https://www.nihr.ac.uk/research-workforce-update-england
All NIHR personal awards are open to foreign nationals. The Global Talent visa includes certain NIHR personal awards under the recognised list of personal fellowships that allows people to apply for a fast-track visa. Further details available at the following link:
https://royalsociety.org/grants/global-talent-visa-overview/route-2-individual-fellowships/
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to improve the recruitment and retention of international researchers working on clinical and cancer research in the UK.
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to improve the recruitment and retention of international researchers working on clinical and cancer research in the UK.
As set out in the Life Sciences Sector Plan and reinforced in the 10-Year Health Plan for England, the Department is committed to cutting the current time it takes to get a clinical trial set up, to under 150 days. I refer the Hon Member to the report, including actions and progress so far against the 150-day target, published by the Government on 9 July 2026, which is available at the following link:
https://www.gov.uk/government/publications/life-sciences-sector-plan-one-year-on
The National Cancer Plan, available at the link below, outlines actions to increase the speed, scale, and reliability of cancer clinical trials in detail:
https://www.gov.uk/government/publications/national-cancer-plan-for-england
The 10-Year Health Plan for England, available at the link below, commits to embedding research as a core component of care:
https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future
An update on the forthcoming 10 Year Workforce Plan will be available in due course.
In July 2026, the Department, through the National Institute for Health and Care Research (NIHR), published the Research Workforce Update for England which aims to ensure that research opportunities and careers are accessible to a broader range of professions and communities, helping to develop a sustainable and inclusive research workforce across all health and social care settings and geographies for the future. The Research Workforce Update for England is available at the following link:
https://www.nihr.ac.uk/research-workforce-update-england
All NIHR personal awards are open to foreign nationals. The Global Talent visa includes certain NIHR personal awards under the recognised list of personal fellowships that allows people to apply for a fast-track visa. Further details available at the following link:
https://royalsociety.org/grants/global-talent-visa-overview/route-2-individual-fellowships/
To ask the Secretary of State for Health and Social Care, what steps she is taking to prioritise access to specialist treatment for rare cancers; how patients with lymphoma are being prioritised; and what progress she has made on meeting commitments in those areas.
To ask the Secretary of State for Health and Social Care, what steps she is taking to prioritise access to specialist treatment for rare cancers; how patients with lymphoma are being prioritised; and what progress she has made on meeting commitments in those areas.
To ask the Secretary of State for Health and Social Care, for (a) brain cancer, (b) breast cancer, (c) lung cancer, (d) bowel cancer and (e) prostate cancer research since 2018, what amount and what percentage of reported public research expenditure consisted of infrastructure, programme or other expenditure not directly...
To ask the Secretary of State for Health and Social Care, for (a) brain cancer, (b) breast cancer, (c) lung cancer, (d) bowel cancer and (e) prostate cancer research since 2018, what amount and what percentage of reported public research expenditure consisted of infrastructure, programme or other expenditure not directly...
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to reduce health inequalities in (a) liver disease and (b) liver cancer outcomes.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to reduce health inequalities in (a) liver disease and (b) liver cancer outcomes.